PCM
TSHA icon

Prelude Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Prelude Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$670K Buy
+98,346
New +$582K 0.05% 415
2024
Q3 		– Sell
-186,591
Closed -$418K – 1549
2024
Q2 		$418K Buy
186,591
+130,698
+234% +$380K 0.03% 622
2024
Q1 		$160K Sell
55,893
-133,983
-71% -$279K 0.01% 1150
2023
Q4 		$336K Sell
189,876
-50,375
-21% -$100K 0.02% 686
2023
Q3 		$759K Buy
+240,251
New +$449K 0.05% 369

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's TSHA Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 98,346 shares worth $670K. The stake represents 0.05% of the portfolio and ranks #415 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in TSHA as recently as Q2 2024.

Prelude Capital Management first reported a position in TSHA in Q3 2023 and has held it in 5 quarters since. The position peaked at $759K in Q3 2023. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Prelude Capital Management held 98,346 shares of Taysha Gene Therapies worth $670K as of Q2 2026.
  • Taysha Gene Therapies was a new Prelude Capital Management position in Q2 2026.
  • Taysha Gene Therapies made up 0.05% of Prelude Capital Management's portfolio in Q2 2026, its #415 holding.
  • Prelude Capital Management first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 5 quarters since.
  • Prelude Capital Management's Taysha Gene Therapies position peaked at $759K in Q3 2023.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.